Post-Graduate Opportunities in Translational Cancer Research

Information Day

Post-Graduate Opportunities in Translational Cancer Research
Date: Friday December 17th 2010
Time: 11:00 – 17:00
Venue: Trinity College Dublin

AGENDA

  • Show case MTCI as a research program
  • Rewards and challenges in translational cancer research
  • Individual research projects available for students within the program
  • Current students
  • Industrial opportunities in cancer field
  • Irish Co-Operative Oncology Research Group (ICORG)
  • Importance of innovation
  • Advantages of undertaking research with MTCI

Are you interested in undertaking a career in Cancer Research and pushing the boundaries of our knowledge into the treatment of cancer? This information day will give you an insight into MTCI and the opportunities that are available to undertake a PhD with principal investigators of the group. Molecular Therapeutics for Cancer Ireland is a Science Foundation Ireland funded Strategic Research Cluster (SRC) which aims to discover and develop new anti-cancer drugs. Under the leadership of Consultant Medical Oncologist, Professor John Crown, with Dublin City University as lead academic institution, the SRC in Molecular Therapeutics for Cancer will assemble and build a fully-integrated national translational cancer drug discovery and development programme.

MTCI is a collaboration of researchers from Dublin City University, University College Dublin/ St Vincent’s University Hospital, Trinity College Dublin/ St. James’ Hospital, Royal College of Surgeons in Ireland with the Irish Cooperative Oncology Research Group as clinical trial partners. Industry partners include GlaxoSmithKline, Pfizer, Merck Sharpe & Dohme, Novartis, Roche, Amgen, Erigal, Caliper Life Sciences and AntiCancer Inc.

For further details and to reserve your place please contact:
Email: Karen Culhane .(JavaScript must be enabled to view this email address)
Tel: +353 (0)1 7007467
Website: http://www.mtci.ie

Please see the information in PDF format. Click here

Leave a comment